Looking Ahead at the Neurology Clinical Trial Space in the Post-COVID-19 Landscape

As head of Biorasi’s Neurology and Regenerative Medicine Centers of Excellence, Dr. El Hokayem oversees clinical projects related to neurological indications and therapies. His unique expertise in the basic, translational and clinical research spectrum provides critical insights at strategic, operational and managerial levels. He is an expert clinical trial decentralizer and an early adopter of digital technologies and digital therapeutics.

With over twenty years’ experience in both academia and clinical research, Dr. El Hokayem has focused his research on rare neurological diseases. He currently serves on the Scientific Advisory Board of the Foundation for Angelman Syndrome Therapeutics (FAST). Dr. El Hokayem has published over twenty peer reviewed papers and received multiple awards from international foundations and entities.

Dr. El Hokayem received his Ph.D. from University of Miami, Miller School of Medicine, in Biochemistry and Molecular Biology. He continued his training with post-doctoral work at the University’s Hussman Institute for Human Genomics.

Dr. Isacson is a Professor of Neurology and Neuroscience at Harvard Medical School and Founding Director of the Neuroregeneration Institute at McLean Hospital. In this role, he is at the forefront of research into neurodegenerative disease and regenerative medicine for brain disorders. He has served as Executive Scientific Advisory Board Member for the Michael J. Fox Foundation and held memberships in the International Parkinson and Movement Society and the FDA’s Cellular, Tissues and Gene Therapies Advisory Committee.

He received his MD and PhD in Medical Neurobiology from the University of Lund in Sweden, completed his research fellowship in Neuroscience at the University of Cambridge, and holds honorary degrees from both Harvard University and University of Lund.